Skip to content

15-epi-lipoxin A4 reduces the mortality of prematurely born pups in a mouse model of infection-induced preterm birth

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)359-68
Number of pages10
JournalMolecular Human Reproduction
Volume21
Issue number4
DOIs
DatePublished - Apr 2015

Abstract

Preterm birth remains the leading cause of neonatal mortality and morbidity worldwide. There are currently few effective therapies and therefore an urgent need for novel treatments. Although there is much focus on trying to alter gestation of delivery, the primary aim of preterm birth prevention therapies should be to reduce prematurity related mortality and morbidity. Given the link between intrauterine infection and inflammation and preterm labour (PTL), we hypothesized that administration of lipoxins, key anti-inflammatory and pro-resolution mediators, could be a useful novel treatment for PTL. Using a mouse model of infection-induced PTL, we investigated whether 15-epi-lipoxin A4 could delay lipopolysaccharide (LPS)-induced PTL and reduce pup mortality. On D17 of gestation mice (n = 9-12) were pretreated with vehicle or 15-epi-lipoxin A4 prior to intrauterine administration of LPS or PBS. Although pretreatment with 15-epi-lipoxin A4 did not delay LPS-induced PTL, there was a significant reduction in the mortality amongst prematurely delivered pups (defined as delivery within 36 h of surgery) in mice treated with 15-epi-lipoxin A4 prior to LPS treatment, compared with those receiving LPS alone (P < 0.05). Quantitative real-time (QRT)-PCR analysis of utero-placental tissues harvested 6 h post-treatment demonstrated that 15-epi-lipoxin A4 treatment increased Ptgs2 expression in the uterus, placenta and fetal membranes (P < 0.05) and decreased 15-Hpgd expression (P < 0.05) in the placenta and uterus, suggesting that 15-epi-lipoxin A4 may regulate the local production and activity of prostaglandins. These data suggest that augmenting lipoxin levels could be a useful novel therapeutic option in the treatment of PTL, protecting the fetus from the adverse effects of infection-induced preterm birth.

Additional information

© The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.

    Research areas

  • Animals, Anti-Inflammatory Agents, Non-Steroidal/pharmacology, Biomarkers/metabolism, Cyclooxygenase 2/genetics, Disease Models, Animal, Female, Fetus/drug effects, Gene Expression, Humans, Hydroxyprostaglandin Dehydrogenases/genetics, Lipopolysaccharides, Lipoxins/pharmacology, Mice, Obstetric Labor, Premature/chemically induced, Placenta/drug effects, Pregnancy, Pregnancy Complications, Infectious/chemically induced, Uterus/drug effects

Documents

DOI

View research connections

Related faculties, schools or groups